The Use of Synthetic Mesh in Reconstructive, Revision, and Cosmetic Breast Surgery

Hilton Becker · Jeffrey G. Lind II

Received: 25 October 2012 / Accepted: 26 May 2013 / Published online: 17 July 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract

Background Recent evidence suggests that the use of acellular dermal matrices in prosthetic breast reconstruction, revision, or augmentation may be associated with an increased risk of complications. In this article we report our results of a potential alternative, using a new long-term resorbable synthetic matrix in these cases.

Methods A retrospective study was performed evaluating 11 primary breast reconstructions (19 breasts), 43 secondary reconstructions (77 breasts), 3 augmentation/augmentation mastopexys (6 breasts), and 5 mastopexys (10 breasts) in 62 patients using TIGR® Matrix Surgical Mesh.

Results Follow-up ranged from 9.4 to 26.1 months with an average follow-up of 16.5 months. Average age was 54 years. The number of patients who had prior radiation was 9 (14.5%). Four patients (6.5%) were smokers. Postoperative breast complications included necrosis of two flaps (1.8%), two seromas requiring drainage (1.8%), four infection/extrusions (3.6%), two relapses of inframammary fold/malposition (1.8%), and two with rippling (1.8%). Other complications included six cases of asymmetry that required a corrective procedure. In a variety of breast surgery cases very good aesthetic results were achieved.

Conclusion The long-term absorbable synthetic matrix, TIGR® Matrix Surgical Mesh, shows potential when used as temporary reinforcement in patients undergoing breast reconstruction or breast surgery revisions and in primary aesthetic procedures, and it appears to be a viable alternative to the use of acellular dermal matrices.

Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors http://www.springer.com/00266.

Keywords Absorbable synthetic surgical mesh · TIGR® Matrix Surgical Mesh · Long-term resorbable surgical mesh · Acellular dermal matrix · Reconstructive breast surgery · Tissue expander implant breast surgery

Introduction

The use of tissue expanders has become the most common technique of performing breast reconstruction as evidenced by the 2011 ASPS Plastic Surgery Statistics Report [2]. Chedomir Radovan, MD, a great innovator of the 1970s, is credited with the development of the Radovan breast expander [31, 32]. He initially described placing tissue expanders in the subcutaneous position. This technique evolved over time leading to the placement of the expander in a submuscular position. This approach to expander-based breast reconstruction is used to maintain total muscle coverage in order to protect the expander from the incision and potential exposure [3]. This technique includes elevating the pectoralis major muscle, serratus anterior muscle, and the anterior fascia of the rectus abdominus muscle [4, 7]. The rigidity of the fascia inferiorly restricts inferior pole expansion and often results in
a high-riding implant. Furthermore, with complete muscle coverage the inframammary fold is ill-defined [29, 30]. Complete muscle coverage was necessary when a more extensive mastectomy was performed in order to protect the implant from exposure beneath the large incision.

The advent of the skin-sparing mastectomy enabled the muscle to be detached inferiorly where the lower skin flap affords coverage to the implant. Although expansion is facilitated with the release of the muscle inferiorly [34], pectoral muscle retraction and bottoming out of the implant became problems [22]. Therefore, the inferior edge of the muscle was sutured to the fascia. However, sutures alone were often ineffective in holding the muscle in position. The tension often resulted in disruption as the sutures cut through the tissues. Acellular dermal matrices (ADM) offered a viable solution to this problem [9, 33, 35, 37]. The ADM reinforces the muscle and also provides supplemental tissue to the space between the released muscle and the inframammary fold. It allows the pectoralis muscle to be released, expands the space, allows fixation of the inframammary fold, and fills in the tissue void between the inferior edge of the pectoralis muscle and the inframammary fold. However, due to recently reported problems encountered with ADM, including seroma, infection, slow vascularization, disruption, reconstructive failure, patient concerns, and costs, we looked at a new long-term resorbable synthetic mesh as a potential alternative [10, 13, 17, 19, 40–43]. Surgical mesh has multiple fixation points thus offering greater tissue fixation compared to sutures. This mesh also functions as a scaffold facilitating native tissue in-growth.

Initially, permanent synthetic meshes (PTFE and Ultrapro) were used but they proved to be too rigid. We then resorted to absorbable mesh (Vicryl), which functioned well for the first few months, but rapid absorption resulted in bottoming out in certain cases. We therefore began using a new synthetic long-term absorbable scaffold known as TIGR® Matrix Surgical Mesh (Novus Scientific Pte Ltd, Singapore). Here we report on the use of this new long-term resorbable synthetic mesh (TIGR® Matrix) in over 50 breast cases. The categories of breast surgery in this study include primary reconstruction, reconstruction revision, augmentation/mastopexy revision, augmentation/mastopexy, and mastopexy. The aim of this study was not to compare TIGR® Matrix to ADMs or other similar products but to look at this mesh as a potential alternative to ADMs in a variety of breast surgery cases. We hypothesize that TIGR® Matrix is a viable alternative to ADMs.

Materials and Methods

A retrospective review was performed on patients who underwent a primary or secondary breast reconstructive surgical procedure as well as patients who underwent a primary aesthetic procedure or aesthetic surgery revision that included the use of TIGR® Matrix Surgical Mesh from 2011 to 2012. All patients meeting these criteria were included. There were no exclusion criteria. All cases were performed by a single surgeon in a private practice setting. Informed verbal and written consent were obtained in all cases. The principles outlined in the Declaration of Helsinki were strictly followed. The smooth Spectrum adjustable implant [5, 6, 8] or a smooth silicone gel implant was used in all cases. Smooth implants were used because our experience does not show an increased frequency of capsular contracture associated with their use. Also, they are easier to work with and have been shown in our experience to have a lower postoperative seroma rate. The adjustable implants were used in all immediate reconstructions where there was a concern about circulation, in patients who had prior radiation, and in cases of excessive scarring. In patients undergoing revision surgery where capsules were present, either capsulectomy or aggressive capsular scoring was performed in order to facilitate vascularization of the mesh. Regular clinical follow-up was done in all patients. Small biopsies of the mesh were taken for histological analysis in patients who had to return to the operating room.

Outpatient charts from this single private practice were reviewed retrospectively. Data collected included patient age, follow-up time, history of prior radiation, history of smoking, reasons for surgery, procedures performed, perioperative findings, postoperative complications, and need for postoperative interventions.

TIGR® Matrix Surgical Mesh is a macroporous mesh knitted from two different degradable fibers: a fast-degrading fiber and a slow-degrading fiber. The fast-degrading fiber is a copolymer between glycolide and trimethylene carbonate, and the slow-degrading fiber is mainly a copolymer between lactide and trimethylene carbonate. The materials used in TIGR® Matrix are all very well known from the suture industry and have been used clinically since 1970 in a vast number of different medical devices [27]. Both fibers degrade into small molecules that are readily absorbed and excreted from the body [20, 28, 39]. The fast-degrading fiber gives extra support during the first wound-healing phase and is totally resorbed within 4 months after implantation. About 2 weeks after implantation TIGR® Matrix will gradually become softer and more flexible due to the ongoing degradation in the fast-degrading fiber, unlocking the knitting pattern of the slow-degrading fiber. The slow-degrading fibers keep their mechanics up to 6–9 months and are completely resorbed after ~3 years due to degradation by hydrolysis [18].
Results

A total of 62 patients (112 breasts) composed the study population. The mean age of the patients at the time of operation was 54 years. Average follow-up was 16.5 months (range 9.4–26.1). No patients were lost to follow-up. Nine patients (14.5 %) had had prior radiation and four patients (6.5 %) were active smokers (Table 1).

Reasons for surgery included capsular contraction, elevation or reconstruction of the inframammary fold, implant removal or replacement, asymmetric primary results, scar revision, and implant repositioning. A total of 11 primary reconstructions (19 breasts), 43 secondary reconstructions (77 breasts), three augmentation/augmentation mastopexys (six breasts), and five mastopexys (10 breasts) were performed using TIGR® Matrix Surgical Mesh. Of the 43 secondary reconstructions, 30 were reconstruction revisions and 13 were augmentation/mastopexy revisions (Table 2).

Perioperative findings included two failed ADM grafts (two patients) as they were fragmented or not integrated at all. Both of these patients had received prior radiation. The biologic material implanted in their primary reconstruction performed at different centers was found to be nonintegrated and ineffective. The ADM grafts were thus removed and replaced with TIGR® Matrix. There were no intraoperative complications.

Very good cosmetic results were obtained in a variety of breast surgery cases (Figs. 1, 2, 34).

The total postoperative complication rate was 20.5 % of breasts. The total postoperative complication rate of patients requiring an intervention was 15.2 % of breasts. Postoperative breast complications included necrosis in two flaps (1.8 %), two seromas (1.8 %), four infection/extrusions (3.6 %), two relapses of inframammary fold/malposition (1.8 %), and two with rippling (1.8 %) (Table 3). Table 4 gives the list of operations and respective complications. All but one patient required an intervention (the one with mild rippling did not need an intervention). Another complication requiring intervention was asymmetry in six cases (5.4 %). Grossly, the mesh was well incorporated with deposited collagen in all patients who had to return to the operating room (Fig. 5). Histological analysis of the incorporated TIGR® Matrix showed the mesh to still be present with surrounding fibroblasts and collagen deposition (Fig. 6).

Table 1 Patient characteristics

| Characteristic                        | Value          |
|--------------------------------------|----------------|
| Average follow-up (months) [min-max] | 16.5 [9.4–26.1]|
| Average age (years)                  | 54             |
| No. of patients with prior radiation | 9 (14.5 %)     |
| No. of smokers                       | 4 (6.5 %)      |

Table 2 Procedures performed

| Procedure                                | No. of patients | No. of breasts |
|------------------------------------------|-----------------|----------------|
| Primary reconstruction                    | 11              | 19             |
| Reconstruction revision                   | 30              | 51             |
| Augmentation/mastopexy revision          | 13              | 26             |
| Augmentation/augmentation mastopexy      | 3               | 6              |
| Mastopexy                                | 5               | 10             |
| Total                                    | 62              | 112            |

Nine patients had a history of radiation and thin skin flaps resulting in a slower healing time and incorporation of the mesh implant. These patients were also found to have very thin skin flaps that required extra attention during the surgical procedure. Of the nine patients who had prior radiation, 44 % developed a postoperative complication. One primary reconstruction patient who had radiation after reconstruction had postoperative infection/extrusion. One secondary reconstruction patient had prior radiation and also experienced postoperative infection/extrusion. Two of the primary reconstruction patients who had prior radiation developed asymmetry that required an additional procedure. Some infection complications were noted early in the series and led to a new routine when placing the drains, using longer subcutaneous tunnels and a longer draining period.
Discussion

Implant-based reconstruction is a very attractive option for women undergoing either therapeutic or prophylactic mastectomy. Those who benefit are patients who lack enough tissue required for autogenous reconstruction, those that have concerns related to donor site morbidities, patients concerned with scarring, and those that want to have little down-time postoperatively. Immediate implant-based reconstruction also has the particular benefit of giving the patient an instant positive psychological advantage. Stevens et al. [37] showed that patients who undergo immediate reconstruction compared to patients who have delayed reconstruction had a lower incidence of psychological morbidity postoperatively.

Immediate breast reconstruction with expanders has been performed using total muscle coverage of the prosthesis to protect the implant from exposure. It became apparent that the rigidity of the muscle often restricted inferior pole expansion resulting in a high-riding implant, an ill-defined inframammary fold, and less than desirable cosmetic results. With skin-sparing and nipple-sparing mastectomy gaining oncologic acceptance [15, 23], immediate implant-based reconstructions of the breast evolved, given the benefit of having a larger skin envelope. Despite the refinement in surgical techniques and the introduction of new prosthetic materials, reconstruction failure and implant dislocation are still common after prosthetic breast reconstruction.

The use of ADM to reinforce the muscle and to provide an increased area of coverage in the inferior pole of the breast led to promising improvements in these reconstructive challenges [9, 33, 35, 38]. Unfortunately, recent literature shows an increased rate of complications associated with the use of ADM in reconstructive breast procedures [10, 13, 17, 19, 21, 24, 40–43]. While this is controversial because there is literature suggesting a low complication profile with the use of ADMs, the experience of the senior author led him to look for alternatives to
**Table 3** Complications

| Complication                  | No. of breasts with complications | % (of total breasts) | No. of breasts requiring intervention |
|-------------------------------|-----------------------------------|----------------------|--------------------------------------|
| Flap necrosis                 | 2                                 | 1.8                  | 2                                    |
| Seroma                        | 2                                 | 1.8                  | 2                                    |
| Infection/extrusion           | 4                                 | 3.6                  | 4                                    |
| Relapse of IMF/malposition    | 2                                 | 1.8                  | 2                                    |
| Rippling                      | 2                                 | 1.8                  | 1                                    |
| Asymmetry                     | 11                                | 9.8                  | 6                                    |
| Total                         | 23                                | 20.5 %               | 17 (15.2 % of total breasts)         |

**Table 4** Operation with associated complications

| Surgery                              | No. of breasts | Flap necrosis | Seroma | Infection/extrusion | Relapse of IMF | Rippling | Asymmetry requiring revision |
|--------------------------------------|----------------|---------------|--------|---------------------|----------------|----------|-----------------------------|
| Primary reconstruction               | 19             | 1             | 2      | 3                   | 0              | 1        | 2                           |
| Reconstruction revision              | 51             | 0             | 0      | 1                   | 1              | 1        | 2                           |
| Augmentation/mastopexy revision      | 26             | 0             | 0      | 0                   | 0              | 0        | 1                           |
| Augmentation/augmentation mastopexy  | 6              | 0             | 0      | 1                   | 0              | 0        | 1                           |
| Mastopexy                            | 10             | 1             | 0      | 0                   | 0              | 0        | 0                           |
ADMs secondary to complications seen in his practice. Some of these complications include seromas, infections, and failure of vascularization. Brooke et al. [11] recently showed a total complication rate in all cases in which ADM was used of 17% compared to 11% in patients who did not receive ADM during reconstruction. Infectious complications were 10% with ADM vs. 2% without ADM. In a large retrospective analysis by Weichman et al. [42], of 628 immediate two-stage breast reconstructions, the use of ADM was associated with a significant increase in major complications. Also in question are the relative mechanical properties between individual sheets of allograft harvested from different donors. A study out of Harvard recently showed that there are statistically significant, highly variable elastic properties between sheets of ADM harvested from different donors [14]. This can be problematic when symmetry is crucial in breast reconstruction.

The use of ADM in corrective reconstructive breast surgery has also been reported in the literature [25, 26, 36]. Given the increasing evidence that ADM may be associated with increased complications, we aimed to examine another option that could prove to be a viable alternative to ADMs when used in select breast cases [1]. In this study we used the TIGR® Matrix Surgical Mesh. The goal of the study was not to compare this product with ADMs or like products but to report on its use as temporary tissue reinforcement in a variety of plastic surgery breast cases.

TIGR® Matrix is the first long-term resorbable synthetic mesh product. It is indicated for reinforcement of soft tissue that is weak and is manufactured from two different synthetic resorbable fibers. It has high strength during the first 6 months following implantation and is completely degraded and resorbed after ~3 years. TIGR® Matrix is manufactured from the well-known and proven materials glycolide, lactide, and trimethylene carbonate, which degrade through hydrolysis and are cleared from the host tissue through normal metabolic pathways. We are now using it as an alternative to ADM in order to aid in correction of breast implant complications such as bottoming out, and as an adjunct in mastopexy surgery. The knitted structure of TIGR® Matrix allows for easy handling and fixation while being strong and flexible. As shown in preclinical trials, it is rapidly vascularized, has a transient inflammatory response, and, over time, is replaced by well-organized connective tissue [18]. This was also our observation during this study. In patients who had a takeback procedure and thus whose mesh was biopsied, there was gross and histological evidence that the mesh was incorporating very nicely and being replaced by well-organized connective tissue. Since its market introduction in 2010, TIGR® Matrix has been used in a variety of plastic and general surgical procedures where soft tissue reinforcement is required, and it has shown excellent results and performance with minimal complications [12].

We were pleased with the results seen in this patient series. The decision to use the matrix was based on the presence or absence of weakness or deficiency of tissue/pectoralis major muscle. In cases in which complete muscle coverage of a prosthesis was the goal, no mesh was used if complete muscle coverage was possible. It is not routine to use mesh in primary aesthetic procedures but it is beneficial at times in mastopexys to hold the tissue in position. The mesh was very easy to work with intraoperatively. The mesh is flexible and has excellent suture-holding ability. We have not encountered any significant restriction to expansion in those cases when the mesh was used. Very good aesthetic results were obtained in a variety of breast cases. Our total complication rate in patients requiring a revision was 15.2%. The complication profile seems reasonable compared to that of ADMs. Specifically, postoperative seroma was seen in only 1.8% of the total breasts reconstructed. The incidence of infections/extrusions was 3.6%. These numbers are lower than those of many published studies referenced in this article. We have
also proven (grossly and histologically) that this mesh incorporates very well into the patient’s native tissue. In order for a surgical mesh to be efficacious, it must allow vascular ingrowth and incorporation into surrounding tissue. This mesh certainly meets these criteria.

Based on our results, a limitation of the matrix may be its use in severely radiated cases, as the complication rate was 44% in patients who had radiation therapy. Complications were more common in radiated cases, with two infections/extrusions and two cases of asymmetry out of the nine patients who had radiation therapy. We now do all radiated-patient revisions in two stages, placing a Spectrum adjustable implant initially in reconstructive cases. Prolonged drainage was necessary in immediate reconstruction, often up to 2 weeks.

Infection complications were noted early in this series and led to a new routine when placing the drains, using longer subcutaneous tunnels and a longer draining period. These corrective actions reduced infections in the latter half of the patient series. Other complications seen included loss of inframammary fold and recurrent ptosis. These complications were seen in earlier cases where the mesh was not adequately positioned. Persistent rippling has also been seen in patients with very thin skin flaps. Overall, we were very pleased with the aesthetic results achieved in this patient series. As expected, there was a natural learning curve to using this new product, and as the study period went by the complication rate dropped off due to changes in technique.

In today’s healthcare environment, cost is becoming more important. A 10-cm × 15-cm sheet of TIGR® Matrix costs $900. This is significantly less than the cost of ADMs and may be one potential advantage of using this matrix [16]. In our study, the cost of the mesh in cosmetic cases was absorbed into the total cost of the procedure.

This study is not without its limitations. First, this is a retrospective study. The sample size is relatively small. While our average follow-up is 16.5 months (longest was 26.1 months), we would like to follow these patients much longer to assess the durability of the postoperative results. A few key surgical techniques were also changed during the course of this study. However, we believe the change in techniques in the latter half of the study would likely improve the results. Also, there were no objective cosmetic assessments performed. However, that was not in the scope of this study. This study was not designed to be a comparative study between TIGR® Matrix and ADMs or between patients receiving TIGR® Matrix versus no mesh. Our goal was to prove that the TIGR® Matrix could be an alternative to ADM when extra tissue support is needed in breast surgery cases.

The results of this study show that the synthetic long-term resorbable mesh TIGR® Matrix Surgical Mesh can be used in patients undergoing implant-based breast reconstruction, breast surgery revisions, or cosmetic breast procedures, and the initial data reveal that it may be a viable alternative to acellular dermal matrices. As the product becomes more widely used and more data become available, we believe that the TIGR® Matrix may have significant value for patients undergoing primary and secondary implant-based breast reconstruction as well as primary aesthetic procedures.

Conclusion

The long-term absorbable synthetic matrix TIGR® Matrix Surgical Mesh appears to have potential when used as temporary tissue reinforcement in patients undergoing breast reconstruction or breast surgery revision as well as primary aesthetic procedures, and it appears to be a possible alternative for acellular dermal matrices.

Conflict of interest Hilton Becker, MD, is a paid consultant of and receives royalties from Mentor Worldwide LLC, and is a consultant to Novus Scientific and Greer Medical. Jeffrey G. Lind II, MD, has no conflicts of interest or financial ties to disclose.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Adetayo OA, Salcedo SE, Bahjri K, Gupta SC (2011) A meta-analysis of outcomes using acellular dermal matrix in breast and abdominal wall reconstructions: event rates and risk factors predictive of complications. Ann Plast Surg. doi:10.1097/SAP.0b013e31822afae5
2. American Society of Plastic Surgeons (2011) Plastic surgery statistics report. Available at http://www.plasticsurgery.org/News-and-Resources/2011-Statistics.html Accessed 16 Oct 2012
3. Becker H (1984) Breast reconstruction using an inflatable breast implant with detachable reservoir. Plast Reconstr Surg 73:678–683
4. Becker H (1987) The expandable mammary implant. Plast Reconstr Surg 79:631–637
5. Becker H (2000) Adjustable breast implants provide postoperative versatility. Aesthet Surg J 20:332
6. Becker H (2004) Breast augmentation using the spectrum implant with exteriorized injection domes. Plast Reconstr Surg 114:1617–1620
7. Becker H (2010) One-stage immediate breast reconstruction with adjustable implants. In: Spear SL, Willey SC, Robb GL, Hammond DC, Nahabedian MY (eds) Surgery of the Breast: Principles and Art, vol 1, 3rd edn. Lippincott Williams and Wilkins, Philadelphia, pp 357–375
8. Becker H, Hartog J (2006) Augmentation mastopexy using adjustable implants with external injection domes. Aesthet Surg J 26:736–740
9. Breuing KH, Warren SM (2005) Immediate bilateral breast reconstruction with implants and inferolateral allodermal slings. Ann Plast Surg 55:232–239
10. Brooke S, Mesa J, Ulmer M et al (2012) Complications in tissue expander breast reconstruction: a comparison of Alloderm, Dermamatrix, and FlexHD acellular inferior pole dermal slings. Plast Reconstr Surg 130(1S):26 (Abstract 24). doi:10.1097/01.prs.0000416112.33447.67
11. Brooke S, Mesa J, Ulmer M et al (2012) Complications in tissue expander breast reconstruction: a comparison of alloderm, dermatamatrix, and flexhd acellular inferior pole dermal slings. Ann Plast Surg 69:347–349
12. Chen OW (2012) 12 month TRAM data collated using TIGR210. Poster presented at the 2012 Malaysian Association of Plastic, Aesthetic, and Craniofacial Surgeons, Penang, Malaysia, 31 Mar 2012
13. Collis GN, Terkonda SP, Waldorf JC, Perdikis G (2012) Acellular dermal matrix slings in tissue expander breast reconstruction: are there substantial benefits? Ann Plast Surg 68:425–428
14. Craft RO, Rebecca AM, Flahive C, Casey WJ 3rd, Daukaus A, Harold KL (2011) Does size matter? technical considerations of a regenerative tissue matrix for use in reconstructive surgery. Can J Plast Surg 9:51–52
15. Fisher B, Redmond C, Poisson R et al (1989) Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 320:822–828
16. Ge PS, Imai TA, Aboulian A, Van Natta TL (2010) The use of human acellular dermal matrix for chest wall reconstruction. Ann Thorac Surg 90:1799–1804
17. Hill JL, Yong L, Kemper P, Buseman J, Davenport DL, Vasconez HC (2012) Infectious complications associated with the use of acellular dermal matrix in implant-based bilateral breast reconstruction. Ann Plast Surg 68:432–434
18. Hjort H, Mathisen T, Alves G, Clermont G, Bouttrand JP (2012) Three-year results from a preclinical implantation study of a long-term resorbable surgical mesh with time-dependent mechanical characteristics. Hernia 16:191–197
19. Ho G, Nguyen TJ, Shabani A, Hwant BH, Chan LS, Wong AK (2012) A systematic review and meta-analysis of complications associated with acellular dermal matrix-assisted breast reconstruction. Ann Plast Surg 68:346–356
20. Katz AR, Mukherjee DP, Kaganov AL, Gordon S (1985) A new synthetic monofilament absorbable suture made from trimethylene carbonate. Surg Gynecol Obstet 161:213–222
21. Kim JYS, Davilla AA, Persing S et al (2012) A meta-analysis of human acellular dermis and submuscular tissue expander breast reconstruction. Plast Reconstr Surg 129:28–41
22. Lesavoy MA, Trussler AP, Dickinson BP (2010) Difficulties with subpectoral augmentation mammaplasty and its correction: the role of subglandular site change in revision aesthetic breast surgery. Plast Reconstr Surg 125:363–371
23. Lichter AS, Lippman ME, Danforth DN Jr et al (1992) Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the national cancer institute. J Clin Oncol 10:976–983
24. Liu AS, Kao HK, Reish RG, Hergrueter CA, May JW Jr, Guo L (2011) Postoperative complications in prosthesis-based breast reconstruction using acellular dermal matrix. Plast Reconstr Surg 127:1755–1762
25. Maxwell GP, Gabriel A (2009) Use of the acellular dermal matrix in revisionary aesthetic breast surgery. Aesthet Surg J 29:485–493
26. Maxwell GP, Gabriel A (2011) Acellular dermal matrix in aesthetic revisionary breast surgery. Aesthet Surg J 31:655–76
27. Middleton JC, Tipton AJ (2000) Synthetic biodegradable polymers as orthopedic devices. Biomaterials 21:2335–2346
28. Miller RA, Brady JM, Cutright DE (1977) Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios. J Biomed Mater Res 11:711–719
29. Namnoum J (2009) Expander/implant reconstruction with AlloDerm: recent experience. Plast Reconstr Surg 124:387–394
30. Parks JW, Hammond SE, Walsh WA, Adams RL, Chandler RG, Luce EA (2012) Human acellular dermis versus no acellular dermis in tissue expansion breast reconstruction. Plast Reconstr Surg 130:739–746
31. Radovan C (1982) Breast reconstruction after mastectomy using the temporary expander. Plast Reconstr Surg 69:195–206
32. Radovan C (1984) Tissue expansion in soft-tissue reconstruction. Plast Reconstr Surg 74:482–490
33. Salzberg CA (2006) Nonexpansive immediate breast reconstruction using human acellular tissue matrix graft (AlloDerm). Ann Plast Surg 57:1–5
34. Serra-Renom JM, Fontdevila J, Monner J, Benito J (2004) Mammary reconstruction using tissue expander and partial detachment of the pectoralis major muscle to expand the lower breast quadrants. Ann Plast Surg 53:317–321
35. Spear SL, Parikh P, Reisin E, Menon N (2008) Acellular dermis-assisted breast reconstruction. Aesthetic Plast Surg 32:418–425
36. Spear SL, Seruya M, Clemens MW, Tetelbaum S, Nahabedian MY (2011) Acellular dermal matrix for the treatment and prevention of implant-associated breast deformities. Plast Reconstr Surg 127:1047–1058
37. Stevens LA, McGrath MH, Druss RG, Kister SJ, Gump FE, Forde KA (1984) The psychological impact of immediate breast reconstruction for women with early breast cancer. Plast Reconstr Surg 73:619–626
38. Vardanian AJ, Clayton JL, Roostaeian J et al (2011) Comparison of implant-based immediate breast reconstruction with and without acellular dermal matrix. Plast Reconstr Surg 128:403e–410e
39. Visscher GE, Robinson RL, Maudling HV, Fong JW, Pearson JE, Argenti GJ (1985) Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. J Biomed Mater Res 19:349–365
40. Wang ED, Lanier ST, Phillips BT et al (2010) Risks and rewards of acellular dermal matrix in tissue expander breast reconstruction: a comparison of Alloderm, Dermal Matrix Surgical Mesh in a randomized controlled study. Presented at the 2012 Malaysian Association of Plastic, Aesthetic, and Reconstructive Surgeons, Penang, Malaysia, 31 Mar 2012
41. Wang ED, Lanier ST, Yilmaz T et al (2010) Acellular dermal matrix surgical mesh in a randomized controlled study. Presented at the 2012 Malaysian Association of Plastic, Aesthetic, and Reconstructive Surgeons, Penang, Malaysia, 31 Mar 2012
42. Weichman KE, Wilson SC, Weinstein AL et al (2012) The use of human acellular dermal matrix slings in tissue expander breast reconstruction. Plast Reconstr Surg 129:1049–1058
43. Wesp, Argentieri GJ (1985) Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. J Biomed Mater Res 19:349–365
44. Novus Scientific Pte Ltd. (2010) Prospective clinical trial on 40 patients with primary inguinal hernia repairs. Paper presented at the American Hernia Society meeting, Orlando, Florida, March 17–20, 2010. Novus Scientific Pte Ltd, Singapore (data on file)